~~<i id='AFD528D475'><strike id='AFD528D475'><tt id='AFD528D475'><pre id='AFD528D475'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

focus

author：focus 2025-09-29 01:45:17 - browse：1

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Paxlovid study fails to answer questions over benefit for broader groups

Wikipedia

hotspot

explore

entertainment

explore

Wikipedia

Whatcausesourearstopopandwhataretheydoing,exactly?AlexHogan,MatthewOrr/STATTakingoffinanairplanealwa

WSS

Hospitals are piloting generative AI tools as regulators play catch

The story of mRNA: From a loose idea to a tool that may help curb Covid

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Why are elite athletes different? Take a look at their microbes

New study raises questions about niacin and heart health

STAT's guide to the next generation of CAR

leisure time

focus

Wikipedia

Tori Bowie and the unacceptable rates of Black maternal death

Researchers tackle phage therapy hurdles for wider adoption

Virginia high school admissions case could be legal follow

Ask STAT: What do you want to know about ChatGPT in medicine?

Hepatitis C has a cure — but many Americans still lack access to it

Medicare Advantage enrollment hits roughly 33.4 million

Supreme Court strikes down use of affirmative action

Paxlovid study fails to answer questions over benefit for broader groups

What does generative AI mean for health care? We asked experts

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

hotspot

Ukraine seeks to reclaim its role as a hub for clinical trials

Colonoscopy at 40? Study finds a possible benefit

What would happen to your eyes if you looked at the solar eclipse?

FDA warns medical device makers about rise in fabricated data

WATCH: Why do fingernails fall off when they're damaged?

Opioid cravings were reduced by anti

explore

entertainment

explore

Wikipedia